The GLP-1 market has split into two camps, and each one wants you to believe the other is either dangerous or a rip-off. Brand-name advocates say compounded medications are unregulated and risky. Compounding advocates say brand-name prices are predatory and that the active ingredient is identical.
Neither side is telling you the whole truth. Here's a breakdown that doesn't cherry-pick data to support a predetermined conclusion.
What's Actually the Same
Let's start with what both camps agree on: the active pharmaceutical ingredient. Brand-name Wegovy and compounded semaglutide both contain semaglutide — a GLP-1 receptor agonist that works by mimicking the incretin hormone to reduce appetite, slow gastric emptying, and improve glycemic control.
The molecular target is the same. The mechanism of action is the same. The expected clinical effects, based on the pharmacology, are the same.
This is the strongest argument for compounded GLP-1s, and it's legitimate: you're not getting a different drug. You're getting the same molecule prepared by a different type of facility.
What's Actually Different
The differences start at the manufacturing level and cascade through every other aspect of the product.
Manufacturing oversight
Brand-name Wegovy is manufactured by Novo Nordisk in FDA-inspected facilities that follow current Good Manufacturing Practices (cGMP). Every batch is tested for potency, purity, sterility, and stability before release. The manufacturing process took years to validate and is continuously monitored.
Compounded semaglutide is prepared by either a 503A compounding pharmacy (regulated by state pharmacy boards) or a 503B outsourcing facility (registered with and inspected by the FDA). The level of oversight varies significantly between these two categories.
Potency consistency
This is where the most uncomfortable data lives. The FDA has tested compounded semaglutide products and found potency variations ranging from 42% to 170% of the labeled amount. That means a vial labeled "5 mg" might contain anywhere from 2.1 mg to 8.5 mg of active ingredient.
Brand-name products are held to a ±10% potency standard. That's a meaningful difference in consistency — and in a medication where dosing precision matters for both efficacy and side effect management, potency variation is not a trivial concern.
Formulation differences
Brand-name Wegovy comes as a pre-filled pen with a fixed dose. You click and inject. There's no math, no drawing from a vial, no calculating concentrations.
Most compounded semaglutide comes as a multi-dose vial that requires the patient to draw the correct volume with a syringe. The concentration varies by pharmacy, so "0.5 mL" doesn't mean the same dose from every vial. This introduces a source of user error that doesn't exist with pre-filled pens.
The semaglutide salt question
Some compounding pharmacies use semaglutide sodium salt rather than semaglutide base form. These are chemically related but not identical — the salt form has a different molecular weight, which affects dose calculations. A vial compounded with semaglutide sodium salt at a labeled concentration that assumes base-form equivalence may deliver a different effective dose than intended.
This is a technical nuance that most patients aren't aware of, and most providers don't explain. It doesn't make compounded semaglutide dangerous — but it adds another variable to an already less standardized product.
The Cost Reality
Brand-name Wegovy has a list price exceeding $1,300/month. With insurance, the out-of-pocket cost varies from $0 (for patients with strong coverage) to several hundred dollars. Without insurance, manufacturer savings programs can reduce the cost — but eligibility isn't universal.
Compounded semaglutide ranges from approximately $99/month to $500/month depending on the provider, dose, and included services. For most patients paying out of pocket, compounded GLP-1s are significantly less expensive.
This cost differential is the primary reason the compounding market exists. For patients without insurance coverage — which includes most people seeking GLP-1s for weight loss — brand-name products are unaffordable, and compounded options provide access to a medication that would otherwise be out of reach.
How to Make This Decision
If you're choosing between brand-name and compounded GLP-1s, here's what to evaluate:
- Check your insurance first. If your plan covers Wegovy or Zepbound with a reasonable copay, brand-name is the simpler choice.
- If going compounded, ask about the pharmacy. What type of facility compounds the medication? Is it 503A or 503B? Can you verify their license? Do they test for potency?
- Ask about the semaglutide form. Is it semaglutide base or semaglutide sodium salt? How are doses calculated?
- Factor in the total cost. A $99/month compounded program with a $99 membership fee and $29 shipping is actually $227/month. Compare apples to apples.
Below are providers representing both compounded and brand-name options:
Providers Worth Investigating
We evaluated these programs based on the criteria discussed in this article. Listings are paid partnerships — our analysis is independent.